Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes

In drug-naive patients with low cardiovascular risk, this systematic review (453 RCTs) found insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) added to metformin-based background therapy produced greatest reductions in hbA1c level.

SPS commentary:

This review also reported that in patients at increased cardiovascular risk, receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favourable effect on certain cardiovascular outcomes.


An editorial discusses the findings and suggest ways that future clinical trials can best inform individualized care for persons with type 2 diabetes.


Annals of Internal Medicine

Resource links: